Literature DB >> 2161048

The pathogenesis of equine herpesvirus type 1 in the mouse: a new model for studying host responses to the infection.

A R Awan1, Y C Chong, H J Field.   

Abstract

An infection was established in adult BALB/c mice by means of intranasal inoculation of the AB4 strain of equine herpesvirus type 1 (EHV-1). The acute infection was confined to the respiratory tract and blood. Virus was shown to replicate in the nasal mucosa, trachea and lung for several days producing clinical signs of disease. Viraemia was also detected and a small proportion of peripheral blood cells contained virus at the peak of the infection. Histological and electron microscopic evidence were obtained which proved that productive virus replication occurred in the ciliated epithelial cells lining the bronchi and in pneumocytes in the lung, resulting in the destruction of these cells. Both humoral and cell-mediated responses to the infection were detected and monitored. By means of immunoprophylaxis or chemotherapy it was possible to modify the course of the infection. This infection model has many striking features in common with that observed in the natural host and the observations suggest that the mouse is a convenient and relevant model in which to study both host responses to EHV-1 infection and modification of the pathogenesis by means of immunoprophylaxis or therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2161048     DOI: 10.1099/0022-1317-71-5-1131

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  18 in total

1.  Severe murine lung immunopathology elicited by the pathogenic equine herpesvirus 1 strain RacL11 correlates with early production of macrophage inflammatory proteins 1alpha, 1beta, and 2 and tumor necrosis factor alpha.

Authors:  P M Smith; Y Zhang; W D Grafton; S R Jennings; D J O'Callaghan
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Immunization with Attenuated Equine Herpesvirus 1 Strain KyA Induces Innate Immune Responses That Protect Mice from Lethal Challenge.

Authors:  Seong K Kim; Akhalesh K Shakya; Dennis J O'Callaghan
Journal:  J Virol       Date:  2016-08-26       Impact factor: 5.103

3.  Modulation of the serological response of specific pathogen-free (EHV-free) foals to EHV-1 by previous infection with EHV-4 or a TK-deletion mutant of EHV-1.

Authors:  D Tewari; J S Gibson; J D Slater; T O'Neill; D Hannant; G P Allen; H J Field
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

4.  The equine herpesvirus 1 Us2 homolog encodes a nonessential membrane-associated virion component.

Authors:  A Meindl; N Osterrieder
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

5.  Characterization of the cytolytic T-lymphocyte response to a candidate vaccine strain of equine herpesvirus 1 in CBA mice.

Authors:  P M Smith; Y Zhang; S R Jennings; D J O'Callaghan
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

6.  CCL3 and viral chemokine-binding protein gg modulate pulmonary inflammation and virus replication during equine herpesvirus 1 infection.

Authors:  Gerlinde R Van de Walle; Kaori Sakamoto; Nikolaus Osterrieder
Journal:  J Virol       Date:  2007-12-12       Impact factor: 5.103

7.  In situ study on the pathogenesis and immune reaction of equine herpesvirus type 1 (EHV-1) infections in mice.

Authors:  T Bartels; F Steinbach; G Hahn; H Ludwig; K Borchers
Journal:  Immunology       Date:  1998-03       Impact factor: 7.397

8.  Reinfection and reactivation of equine herpesvirus-1 in the mouse.

Authors:  H J Field; A R Awan; R de la Fuente
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

9.  Pathogenesis of equine herpesvirus-1 in specific pathogen-free foals: primary and secondary infections and reactivation.

Authors:  J S Gibson; J D Slater; A R Awan; H J Field
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

10.  Effective treatment of respiratory alphaherpesvirus infection using RNA interference.

Authors:  Amy Fulton; Sarah T Peters; Gillian A Perkins; Keith W Jarosinski; Armando Damiani; Margaret Brosnahan; Elizabeth L Buckles; Nikolaus Osterrieder; Gerlinde R Van de Walle
Journal:  PLoS One       Date:  2009-01-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.